1411 related articles for article (PubMed ID: 32605588)
21. Analysis of the miRNA-mRNA-lncRNA networks in ER+ and ER- breast cancer cell lines.
Wu Q; Guo L; Jiang F; Li L; Li Z; Chen F
J Cell Mol Med; 2015 Dec; 19(12):2874-87. PubMed ID: 26416600
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
Lowery AJ; Miller N; Devaney A; McNeill RE; Davoren PA; Lemetre C; Benes V; Schmidt S; Blake J; Ball G; Kerin MJ
Breast Cancer Res; 2009; 11(3):R27. PubMed ID: 19432961
[TBL] [Abstract][Full Text] [Related]
23. In Silico Identification of a BRCA1:miR-29:DNMT3 Axis Involved in the Control of Hormone Receptors in BRCA1-Associated Breast Cancers.
Santarosa M; Baldazzi D; Armellin M; Maestro R
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373065
[TBL] [Abstract][Full Text] [Related]
24. Differential microRNA expression in breast cancer with different onset age.
Tsai HP; Huang SF; Li CF; Chien HT; Chen SC
PLoS One; 2018; 13(1):e0191195. PubMed ID: 29324832
[TBL] [Abstract][Full Text] [Related]
25. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
26. Screening biomarkers of bladder cancer using combined miRNA and mRNA microarray analysis.
Jin N; Jin X; Gu X; Na W; Zhang M; Zhao R
Mol Med Rep; 2015 Aug; 12(2):3170-6. PubMed ID: 25955758
[TBL] [Abstract][Full Text] [Related]
27. Coordinated regulation of WNT/β-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits.
Giacomelli C; Jung J; Wachter A; Ibing S; Will R; Uhlmann S; Mannsperger H; Sahin Ö; Yarden Y; Beißbarth T; Korf U; Körner C; Wiemann S
BMC Cancer; 2021 Dec; 21(1):1296. PubMed ID: 34863149
[TBL] [Abstract][Full Text] [Related]
28. Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease.
Qattan A
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255471
[TBL] [Abstract][Full Text] [Related]
29. Identification of a Gene Expression Signature to Predict the Risk of Early Recurrence and the Degree of Immune Cell Infiltration in Triple-negative Breast Cancer.
Sato K; Miura K; Tamori S; Akimoto K
Cancer Genomics Proteomics; 2024; 21(3):316-326. PubMed ID: 38670590
[TBL] [Abstract][Full Text] [Related]
30. Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer.
Lehmann TP; Korski K; Gryczka R; Ibbs M; Thieleman A; Grodecka-Gazdecka S; Jagodziński PP
Mol Med Rep; 2015 Sep; 12(3):4692-4702. PubMed ID: 26130254
[TBL] [Abstract][Full Text] [Related]
31. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
Pronina IV; Loginov VI; Burdennyy AM; Fridman MV; Senchenko VN; Kazubskaya TP; Kushlinskii NE; Dmitriev AA; Braga EA
Gene; 2017 Mar; 604():1-8. PubMed ID: 27998789
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.
Matamala N; Vargas MT; González-Cámpora R; Arias JI; Menéndez P; Andrés-León E; Yanowsky K; Llaneza-Folgueras A; Miñambres R; Martínez-Delgado B; Benítez J
Oncotarget; 2016 Apr; 7(15):20068-79. PubMed ID: 26933805
[TBL] [Abstract][Full Text] [Related]
33. Identification of differentially expressed genes between triple and non-triple-negative breast cancer using bioinformatics analysis.
Zhai Q; Li H; Sun L; Yuan Y; Wang X
Breast Cancer; 2019 Nov; 26(6):784-791. PubMed ID: 31197620
[TBL] [Abstract][Full Text] [Related]
34. Race Disparities in the Contribution of miRNA Isoforms and tRNA-Derived Fragments to Triple-Negative Breast Cancer.
Telonis AG; Rigoutsos I
Cancer Res; 2018 Mar; 78(5):1140-1154. PubMed ID: 29229607
[TBL] [Abstract][Full Text] [Related]
35. A panel of miRNAs as prognostic markers for African-American patients with triple negative breast cancer.
Turkistani S; Sugita BM; Fadda P; Marchi R; Afsari A; Naab T; Apprey V; Copeland RL; Campbell MC; Cavalli LR; Kanaan Y
BMC Cancer; 2021 Jul; 21(1):861. PubMed ID: 34315420
[TBL] [Abstract][Full Text] [Related]
36. A systems biology approach and in vitro experiment indicated Rapamycin targets key cancer and cell cycle-related genes and miRNAs in triple-negative breast cancer cells.
Tafti A; Shojaei S; Zali H; Karima S; Mohammadi-Yeganeh S; Mondanizadeh M
Mol Carcinog; 2023 Dec; 62(12):1960-1973. PubMed ID: 37787375
[TBL] [Abstract][Full Text] [Related]
37. miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers.
Fkih M'hamed I; Privat M; Trimeche M; Penault-Llorca F; Bignon YJ; Kenani A
Pathol Oncol Res; 2017 Oct; 23(4):815-827. PubMed ID: 28101798
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L
Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450
[TBL] [Abstract][Full Text] [Related]
39. Differentially expressed microRNAs in exosomes of patients with breast cancer revealed by next‑generation sequencing.
Wu H; Wang Q; Zhong H; Li L; Zhang Q; Huang Q; Yu Z
Oncol Rep; 2020 Jan; 43(1):240-250. PubMed ID: 31746410
[TBL] [Abstract][Full Text] [Related]
40. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study.
Moi L; Braaten T; Al-Shibli K; Lund E; Busund LR
J Transl Med; 2019 Oct; 17(1):334. PubMed ID: 31581940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]